NASDAQ: AGLEAeglea Biotherapeutics Inc Stock
$11.86+0.19 (+1.63%)
Updated Sep 22, 2023
AGLE Price
$11.86
Fair Value Price
$21.21
Market Cap
$48.01M
52 Week Low
$2.66
52 Week High
$39.00
P/E
-0.17x
P/B
-0.23x
P/S
35.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.23M
Earnings
-$272.56M
Gross Margin
100%
Operating Margin
-22,211.64%
Profit Margin
-22,195.4%
Debt to Equity
-1.22
Operating Cash Flow
-$67M
Beta
1.18
Next Earnings
Nov 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A
AGLE Overview
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Zen Score
–
Industry Average (24)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AGLE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AGLE ($11.86) is undervalued by 44.08% relative to our estimate of its Fair Value price of $21.21 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AGLE ($11.86) is significantly undervalued by 44.08% relative to our estimate of its Fair Value price of $21.21 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AGLE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AGLE due diligence checks available for Premium users.
Be the first to know about important AGLE news, forecast changes, insider trades & much more!
AGLE News
Valuation
AGLE fair value
Fair Value of AGLE stock based on Discounted Cash Flow (DCF)
Price
$11.86
Fair Value
$21.21
Undervalued by
44.08%
AGLE ($11.86) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AGLE ($11.86) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AGLE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AGLE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.17x
Industry
12.89x
Market
14.52x
AGLE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.23x
Industry
5.11x
AGLE's financial health
Profit margin
Revenue
$688.0k
Net Income
-$217.1M
Profit Margin
-31,552.5%
AGLE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AGLE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$243.5M
Liabilities
$253.6M
Debt to equity
-1.22
AGLE's short-term assets ($239.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AGLE's short-term assets ($239.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AGLE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AGLE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.6M
Investing
$6.8M
Financing
$210.0M
AGLE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AGLE vs Biotech Stocks
Aeglea Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.